Rapid emergency department heart failure outpatients trial (REDHOT II): A randomized controlled trial of the effect of serial B-type natriuretic peptide testing on patient management

Circulation: Heart Failure

Volumn 2, Issue 4, 2009, Pages 287-293

  Singer, Adam J ^b   Birkhahn, Robert H ^a   Guss, David ^a   Chandra, Abhinav ^c   Miller, Chadwick D ^d   Tiffany, Brian ^g   Levy, Phillip ^e   Dunne, Robert ^f   Bastani, Aveh ^a   Thode Jr , Henry C ^b   Hollander, Judd E ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c San Diego   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e WAKE FOREST SCHOOL OF MEDICINE   (United States)

^f WAYNE STATE UNIVERSITY   (United States)

^g UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Acute heart failure; B type natriuretic peptide; Mortality; Point of care testing

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLYCERYL TRINITRATE; HEPARIN; INOTROPIC AGENT; NESIRITIDE;

ACUTE HEART FAILURE; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EMERGENCY WARD; FEMALE; HOSPITAL READMISSION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTPATIENT CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

FEMALE; HEART FAILURE; HOSPITAL MORTALITY; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PATIENT READMISSION; PREDICTIVE VALUE OF TESTS;

EID: 70450249996     PISSN: 19413289     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.108.826685     Document Type: Article

References (23)

1. AHA. American Heart Association Heart Disease and Stroke Statis-tics-2006 Update. Dallas, TX: AHA; 2006.
2. Krumholz W. Cost and cost-effectiveness studies in heart failure research. Am Heart J. 2002;143:565-576.
3. Adams KF Jr, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT, Berkowitz RL, Galvao M, Horton DP; ADHERE Scientific Advisory Committee and Investigators. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2005;149:209-216.
4. Bales AC, Sorrentino MJ. Causes of congestive heart failure: prompt diagnosis may affect prognosis. Postgrad Med. 1997;1010:44-46.
5. Wuerz RC, Meador SA. Effects of prehospital medications on mortality and length of stay in congestive heart failure. Ann Emerg Med. 1992;21: 669-674.
6. Baughman KL. B-type natriuretic peptide: a window to the heart. N Engl J Med. 2002;347:158-159.
7. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, Omland T, Storrow AB, Abraham WT, Wu AH, Clopton P, Steg PG, Westheim A, Knudsen CW, Perez A, Kazanegra R, Herrmann HC, McCullough PA; Breathing Not Properly Multinational Study Investigators. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347:161-167.
8. McCullough PA, Nowak RM, McCord J, Hollander JE, Herrmann HC, Steg PG, Duc P, Westheim A, Omland T, Knudsen CW, Storrow AB, Abraham WT, Lamba S, Wu AH, Perez A, Clopton P, Krishnaswamy P, Kazanegra R, Maisel AS. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study. Circulation. 2002;106:416-422.
9. Maisel A, Hollander JE, Guss D, McCullough P, Nowak R, Green G, Saltzberg M, Ellison SR, Bhalla MA, Bhalla V, Clopton P, Jesse R; Rapid Emergency Department Heart Failure Outpatient Trial Investigators. Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. J Am Coll Cardiol. 2004; 44:1328-1333.
10. Cheng V, Kazanagra R, Garcia A, Lenert L, Krishnaswamy P, Gardetto N, Clopton P, Maisel A. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol. 2001;37:386-391.
11. Harrison A, Morrison LK, Krishnaswamy P, Kazanegra R, Clopton P, Cao Q, Hlavin P, Maisel AS. B-type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea. Ann Emerg Med. 2002;39:131-138.
12. Betteencourt P, Ferreira S, Azevedo A, Ferreiera A. Preliminary data on the potential usefulness of B-type natriuretic peptide levels in predicting outcomes after hospital discharge in patients with heart failure. Am J Med. 2002;113:215-219.
13. Mueller C, Scholer A, Laule-Kilian K, Martina B, Schindler C, Buser P, Pfisterer M, Perruchoud AP. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med. 2004;350: 647-654. (Pubitemid 38364623)
14. Fonarow GC, Adams KF Jr, Abraham WT, Yancy CW, Boscardin WJ; ADHERE Scientific Advisory Committee, Study Group, and Investi- gators. Risk stratification for in-hospital mortality in acutely decom- pensated heart failure: classification and regression tree analysis. JAMA. 2005;293:572-580.
15. Fonarow GC, Peacock WF, Phillips CO, Givertz MM, Lopatin M; ADHERE Scientific Advisory Committee and Investigators. Admission B-type natriuretic peptide levels and in-hospital mortality in acute decom- pensated heart failure. J Am Coll Cardiol. 2007;49:1943-1950.
16. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet. 2000; 355:1126-1130.
17. Murdoch DR, McDonagh TA, Byrne J, Blue L, Farmer R, Morton JJ, Dargie HJ. Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy. Am Heart J. 1999;138:1126-1132.
18. Jourdain P, Jondeau G, Funck F, Gueffet P, Le Helloco A, Donal E, Aupetit JF, Aumont MC, Galinier M, Eicher JC, Cohen-Solal A, Juilliere Y. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J Am Coll. 2007;49: 1733-1739.
19. Nishii M, Inomata T, Takehana H, Naruke T, Yanagisawa T, Moriguchi M, Takeda S, Izumi T. Prognostic utility of B-type natriuretic peptide assessment in stable low-risk outpatients with nonischemic cardiomy-opathy after decompensated heart failure. J Am Coll Cardiol. 2008;51: 2329-2335.
20. Beck-da-Silva L, de Bold A, Fraser M, Williams K, Haddad H. BNP- guided therapy not better than expert's clinical assessment for beta-blocker titration in patients with heart failure. Congest Heart Fail. 2005; 11:248-253.
21. Miller WL, Hartmen KA, Burritt MF, Grill DE, Rodeheffer RJ, Burnett JC Jr, Jaffe AS. Serial biomarker measurements in ambulatory patients with chronic heart failure. Circulation. 2007;116:249-257.
22. Valle R, Aspromonte N, Carbonieri E, D'Eri A, Feola M, Giovinazzo P, Noventa F, Prevaldi C, Barro S, Milani L. Fall in readmission rate for heart failure after implementation of B-type natriuretic peptide testing for discharge decision: a retrospective study. Int J Cardiol. 2008;126: 400-406.
23. Pfisterer M, Buser P, Rickli H, Gutmann M, Erne P, Rickenbacher P, Vuillomenet A, Jeker U, Dubach P, Beer H, Yoon SI, Suter T, Osterhues HH, Schieber MM, Hilti P, Schindler R, Brunner-La Rocca HP; TIME-CHF Investigators. BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients with Congestive Heart Failure (TIME-CHF) randomized trial. JAMA. 2009;301:383-392.